Testosterone tridecanoate is under clinical development by Lipocine and currently in Phase II for Hepatic Encephalopathy. According to GlobalData, Phase II drugs for Hepatic Encephalopathy have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Testosterone tridecanoate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Testosterone tridecanoate overview
Testosterone tridecanoate is under development for the management of decompensated liver cirrhosis in sarcopenia, secondary sarcopenia, hepatic encephalopathy. It is a prodrug of testosterone laurate. The drug candidate is administered through oral route as capsule formulation. It acts by targeting androgen receptor and is being developed based on Lip'ral technology.
It was under development for the treatment of non-alcoholic steatohepatitis.
Lipocine overview
Lipocine operates as a pharmaceutical company that develops and commercializes treatments for men’s and women’s health. The company’s pipeline products for men’s health include LPCN 1111, LPCN 1144, LPCN 1021 and for women’s health include LPCN 1107. It’s LPCN 1111 is an oral testosterone product candidate and LPCN 1021 is an oral testosterone replacement therapy with a positive topline. Lipocine offers LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of preterm birth. LPCN 1144 is a oral prodrug of bioidentical testosterone for the treatment of non alcoholic steatohepatitis. Lipocine is headquartered in Salt Lake City, Utah, US.
For a complete picture of Testosterone tridecanoate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
